Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2022 May Clinical trials Outcomes in adolescent and young adult patients compared to younger patients treated for high-... Read more
2022 May Prevention Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic ... Read more
2022 May Clinical practice 2021 Update on measurable residual disease in acute myeloid leukaemia Read more
2022 May Science Flow cytometric MRD assessment in B-cell precursor ALL patients treated with CD19-targeted the... Read more
2022 May ASH 2021 Mosunetuzumab: effective and well-tolerated in the treatment of relapsed/refractory follicular... Read more
2022 March Editor's pick RELEVANT LITERATURE FOR YOUR DAILY PRACTICE SELECTED BY: DOMINIQUE BRON Read more
Top
